Free tool
Rare disease stocks
We cover 4 companies grouped under the Rare disease theme. The median market value in the group is $6.57B. Across the group, the median move over the past trading day is −0.01%. Price change over the past year runs from +27.3% to +258.4% across the middle 80 percent of the group, with a median of +117.5%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| 0HNC.L | BioMarin Pharmaceutical Inc. | $66.19 | +0.05% | +11.54% | +15.03% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $84.84 | +1.17% | +81.55% | +179.08% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $37.08 | +89.67% | +224.69% | +292.38% |
| CPRX | Catalyst Pharmaceuticals Inc | $31.49 | 0.00% | +36.03% | +55.97% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.